Login
$STLN
$3.50 -$0.04 (1.13%) After hours

$STLN 8-K SEC Filings

Filed On Filing
12 Nov 2026 8-K: Regulation FD Disclosure

Some of the information in this presentation is not historical in nature and may constitute forward - looking statements, which ar e made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The...

05 Nov 2026 8-K: Results of Operations and Financial Condition

CERRITOS, Calif., November 5, 2026 -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its quarter ended...

02 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation

On September 1, 2026, Brad Hively notified Starling Oncology, Inc. (the “Company”) of his decision to not stand for re-election to the Board of the Directors of the Company (the “Board”) at its 2027 annual meeting of stockholders (the “A...

21 Aug 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

STARLING ONCOLOGY MANAGEMENT, LIMITED LIABILITY COMPANY f/k/a TOI MANAGEMENT, LLC

06 Aug 2026 8-K: Results of Operations and Financial Condition

CERRITOS, Calif., August 6, 2026 -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its quarter ended J...

03 Aug 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Regulation FD Disclosure

Company to begin trading on Nasdaq under new ticker symbol “STLN,” replacing “TOI”

07 Jul 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more

Exhibit A-Form of Promissory Note Exhibit B-Form of Loan Request Exhibit C-Form of Compliance Certificate Exhibit D-Form of Guarantee Exhibit E-Form of Security Agreement

18 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 17, 2026, The Oncology Institute, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) in which the Company’s holders of Common Stock considered four proposals, each of which is described ...

22 May 2026 8-K: Material Cybersecurity Incidents

The Oncology Institute, Inc. (the “Company”) is providing this disclosure, as a follow-up to its voluntary disclosure in Item 7.01 of a Current Report on Form 8-K filed on November 6, 2025, regarding a cybersecurity incident affecting a ...

07 May 2026 8-K: Results of Operations and Financial Condition

CERRITOS, Calif., May 7, 2026 -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months en...

13 Mar 2026 8-K: Regulation FD Disclosure

The Oncology Institute, Inc. (the “Company”) has prepared an investor presentation (the “Investor Presentation”) to use in meetings with investors. A copy of the Investor Presentation is furnished as Exhibit 99.1 to this Current Report o...

12 Mar 2026 8-K: Results of Operations and Financial Condition

CERRITOS, Calif., March 12, 2026 -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quart...

23 Feb 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

CERRITOS, Calif., Feb 23, 2026 (Global NEWSWIRE) – The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced the appointment of Kim Tzoumakas to its Board of ...

12 Jan 2026 8-K: Results of Operations and Financial Condition

CERRITOS, Calif., January 12, 2026 (GLOBE NEWSWIRE) – The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based oncology groups in the United States, today reaffirmed 2025 guidance and provided i...

07 Jan 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

CERRITOS, Calif., January 5, 2026 (GLOBE NEWSWIRE) – The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Mark Stolper has joined the Board of Direc...

01 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

CERRITOS, Calif., December 1, 2025 (GLOBE NEWSWIRE) – The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Gabe Ling has resigned from the Board of ...

14 Nov 2025 8-K: Regulation FD Disclosure

1 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION (µáÌÒºÈʼn Lȏ̏µÒyÒ¡ºµ <ºá´…ÈʼnĉćĉČ

13 Nov 2025 8-K: Results of Operations and Financial Condition

CERRITOS, Calif., November 13, 2025 -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its three mon...

06 Nov 2025 8-K: Regulation FD Disclosure

On November 3, 2025, The Oncology Institute, Inc. (the “Company”) determined that a cybersecurity incident affecting an information technology software provider would potentially delay fee-for-service collections. Based on the Company's ...

13 Aug 2025 8-K: Results of Operations and Financial Condition

CERRITOS, Calif., August 13, 2025 -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its three month...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support